An ethical case explores a 70-year-old man diagnosed with pancreatic cancer who wants to have his pacemaker turned off in order to hasten what he fears may be an unpleasant death.
An ethical case explores a 70-year-old man diagnosed with pancreatic cancer who wants to have his pacemaker turned off in order to hasten what he fears may be an unpleasant death.
New guidelines and the continuous modification of current policies will be needed in order to establish and maintain an appropriate professional relationship between physicians and pharmaceutical companies.
The authors of a recent journal article believe that most doctors and clinical trial sponsors would not object to changes in regulations requiring doctors to disclose financial incentives to their patients.
Douglas E. Paull, MD, MS and Paul N. Uhlig, MD, MPA
Risk managers can help patient-subjects and clinician-researchers make informed novel device implantation decisions in the absence of preclinical trial data.
AMA J Ethics. 2020; 22(11):E911-918. doi:
10.1001/amajethics.2020.911.